Detalhe da pesquisa
1.
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood
; 139(8): 1198-1207, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34469514
2.
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Blood
; 140(20): 2127-2141, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35709339
3.
How I treat chronic lymphocytic leukemia after venetoclax.
Blood
; 138(5): 361-369, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876212
4.
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Intern Med J
; 53(9): 1678-1691, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743239
5.
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Blood
; 135(25): 2266-2270, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244251
6.
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Blood
; 129(25): 3362-3370, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28473407
7.
Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.
Br J Haematol
; 197(4): 394-396, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35262916
8.
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.
Intern Med J
; 52(7): 1286-1287, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35879233
9.
Early serum creatinine accurately predicts acute kidney injury post cardiac surgery.
BMC Nephrol
; 18(1): 93, 2017 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28302078
10.
Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency.
Acta Haematol
; 130(4): 254-9, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23860572
11.
Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease.
Leuk Lymphoma
; 64(11): 1792-1800, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37531077
12.
Treatment approaches for patients with TP53-mutated mantle cell lymphoma.
Lancet Haematol
; 10(2): e142-e154, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725119
13.
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.
J Hematol Oncol
; 15(1): 75, 2022 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35659041
14.
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blood Adv
; 6(20): 5589-5592, 2022 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901282
15.
Rehabilitation in patients with lymphoma: An overview of Systematic Reviews.
J Rehabil Med
; 53(3): jrm00163, 2021 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33710351
16.
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.
Blood Adv
; 5(20): 4054-4058, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34478505
17.
Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.
Cancer Drug Resist
; 3(3): 415-444, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-35582452
18.
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.
Blood Adv
; 4(1): 165-173, 2020 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31935286
19.
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Blood Adv
; 8(6): 1439-1443, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231032
20.
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Cancer Discov
; 9(3): 342-353, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514704